Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Open Forum Infectious Diseases|August 21, 2023
Additional Burden Averted in the United States From Use of MF59-Adjuvanted Seasonal Influenza Vaccine Compared With Standard Seasonal Influenza Vaccine Among Adults ≥65 YearsIan McGovern, Aditya Sardesai, Alexandra Taylor, et al.
Expert Review of Vaccines|March 18, 2024
Influenza burden averted with a cell-based quadrivalent seasonal influenza vaccine compared with egg-based quadrivalent seasonal influenza vaccineIan McGovern, Alexandra Taylor, Aditya Sardesai, et al.
Infectious Diseases and Therapy|September 5, 2024
Disease Burden Associated with All Infants in Their First RSV Season in the UK: A Static Model of Universal Immunization with Nirsevimab Against RSV-Related OutcomesAlexia Kieffer, Matthieu Beuvelet, Gerald Moncayo, et al.
Neurology and Therapy|March 17, 2023
Estimated Societal Value of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation ModelingAmir Abbas Tahami Monfared, Weicheng Ye, Aditya Sardesai, et al.
Neurology and Therapy|April 3, 2023
A Path to Improved Alzheimer's Care: Simulating Long-Term Health Outcomes of Lecanemab in Early Alzheimer's Disease from the CLARITY AD TrialAmir Abbas Tahami Monfared, Weicheng Ye, Aditya Sardesai, et al.
The Journal of Infectious Diseases|August 15, 2022
Expected Impact of Universal Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants in Their First RSV Season: A Static ModelAlexia Kieffer, Matthieu Beuvelet, Aditya Sardesai, et al.
Journal of Medical Economics|January 27, 2021
Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in GermanyAditya Sardesai, Axel Dignass, Peter Quon, et al.
Neurology and Therapy|May 15, 2023
Predicting the Societal Value of Lecanemab in Early Alzheimer's Disease in Japan: A Patient-Level SimulationAtaru Igarashi, Mie Kasai Azuma, Quanwu Zhang, et al.
BMC Infectious Diseases|September 6, 2024
Modelling the potential clinical and economic impact of universal immunisation with nirsevimab versus standard of practice for protecting all neonates and infants in their first respiratory syncytial virus season in SpainRuth Gil-Prieto, Jaime Jesus Pérez, Georgina Drago, et al.
Pageof 1